Simultaneous exposure of transformed cells to SRC family inhibitors and CHK1 inhibitors causes cell death

Cancer Biology and Therapy

Volumn 12, Issue 3, 2011, Pages 215-228

  Mitchell, Clint ^a   Hamed, Hossein A ^a   Cruickshanks, Nichola ^a   Tang, Yong ^a   Bareford, M Danielle ^a   Hubbard, Nisan ^a   Tye, Gary ^a   Yacoub, Adly ^a   Dai, Yun ^b   Grant, Steven ^b   Dent, Paul ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Breast cancer; Caspase; CHK1; Intrinsic; Kinase; SRC; Therapeutics

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; 4 AMINO 7 TERT BUTYL 5 (4 CHLOROPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; 7 HYDROXYSTAUROSPORINE; AZD 7762; DASATINIB; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL XL; PROTEIN SERINE THREONINE KINASE INHIBITOR; PROTEIN TYROSINE KINASE; SARACATINIB; SELUMETINIB; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BREAST CANCER; CANCER CELL; CELL DEATH; CELL TRANSFORMATION; CONTROLLED STUDY; CYTOTOXICITY; EMBRYO; FIBROBLAST; GENETIC MODEL; HUMAN; HUMAN CELL; MOUSE; NONHUMAN;

ANIMALS; BCL-2 HOMOLOGOUS ANTAGONIST-KILLER PROTEIN; BCL-2-ASSOCIATED X PROTEIN; BCL-X PROTEIN; BENZIMIDAZOLES; BENZODIOXOLES; BREAST NEOPLASMS; CELL DEATH; CELL LINE, TRANSFORMED; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; FIBROBLASTS; HUMANS; MAP KINASE KINASE 1; MAP KINASE KINASE 2; MICE; PROTEASE INHIBITORS; PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-FYN; PROTO-ONCOGENE PROTEINS C-YES; PYRIMIDINES; QUINAZOLINES; RADIATION TOLERANCE; SRC-FAMILY KINASES; THIAZOLES;

EID: 79961240240     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.12.3.16218     Document Type: Article

References (46)

1. Mow BM, Blajeski AL, Chandra J, Kaufmann SH. Apoptosis and the response to anticancer therapy. Curr Opin Oncol 2001; 13:453-62. (Pubitemid 33027897)
2. Prudhomme M. Novel checkpoint 1 inhibitors. Recent Patents Anticancer Drug Discov 2006; 1:55-68.
3. Graves PR, Yu L, Schwarz JK, Gales J, Sausville EA, O'Connor PM, et al. The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01. J Biol Chem 2000; 275:5600-5. (Pubitemid 30115197)
4. Peng CY, Graves PR, Thoma RS, Wu Z, Shaw AS, Piwnica-Worms H. Mitotic and G checkpoint control: regulation of 14-3-3 protein binding by phosphorylation of Cdc25C on serine-216. Science 1997; 277:1501-5. (Pubitemid 27449237)
5. Komander D, Kular GS, Bain J, Elliott M, Alessi DR, Van Aalten DM. Structural basis for UCN-01 (7-hydroxystaurosporine) specificity and PDK1 (3-phosphoinositide-dependent protein kinase-1) inhibition. Biochem J 2003; 375:255-62. (Pubitemid 37315433)
6. Sausville EA, Lush RD, Headlee D, Smith AC, Figg WD, Arbuck SG, et al. Clinical pharmacology of UCN-01: initial observations and comparison to preclinical models. Cancer Chemother Pharmacol 1998; 42:54-9.
7. Fuse E, Kuwabara T, Sparreboom A, Sausville EA, Figg WD. Review of UCN-01 development: a lesson in the importance of clinical pharmacology. J Clin Pharmacol 2005; 45:394-403. (Pubitemid 40490412)
8. Hagenauer B, Maier-Salamon A, Thalhammer T, Zollner P, Senderowicz A, Jager W. Metabolism of UCN-01 in isolated perfused rat liver: role of Mrp2 in the biliary excretion of glucuronides. Oncol Rep 2004; 11:1069-75.
9. Fuse E, Tanii H, Kurata N, Kobayashi H, Shimada Y, Tamura T, et al. Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human alpha1-acid glycoprotein. Cancer Res 1998; 58:3248-53. (Pubitemid 28371060)
10. Dees EC, Baker SD, O'Reilly S, Rudek MA, Davidson SB, Aylesworth C, et al. A phase I and pharmacokinetic study of short infusions of UCN-01 in patients with refractory solid tumors. Clin Cancer Res 2005; 11:664-71. (Pubitemid 40116893)
11. Hotte SJ, Oza A, Winquist EW, Moore M, Chen EX, Brown S, et al. Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers: a Princess Margaret Hospital Phase II Consortium study. Ann Oncol 2006; 17:334-40. (Pubitemid 43160126)
12. Perez RP, Lewis LD, Beelen AP, Olszanski AJ, Johnston N, Rhodes CH, et al. Modulation of cell cycle progression in human tumors: a pharmacokinetic and tumor molecular pharmacodynamic study of cisplatin plus the Chk1 inhibitor UCN-01 (NSC 638850). Clin Cancer Res 2006; 12:7079-85. (Pubitemid 44974507)
13. Lexpression on taxol-induced apoptosis and cytotoxicity in human leukemia cells (U937). Leukemia 1999; 13:1564-73.
14. Dent P, Yacoub A, Fisher PB, Hagan MP, Grant S. MAPK pathways in radiation responses. Oncogene 2003; 22:5885-96. (Pubitemid 37176709)
15. Dent P, Qiao L, Grant S. Signaling by ErbB family receptors. Frontiers in Bioscience 2002; 376-89.
16. McKinstry R, Qiao L, Yacoub A, Dai Y, Decker R, Holt S, et al. Pharmacologic inhibitors of the mitogen activated protein kinase cascade interact synergistically with UCN-01 to induce mitochondrial dysfunction and apoptosis in mammary and prostate carcinoma cells. Cancer Biol Ther 2002; 1:241-51.
17. Dai Y, Decker RH, McKinstry R, Dent P, Grant S. Pharmacologic inhibitors of the mitogen activated protein kinase cascade interact synergistically with UCN-01 to induce mitochondrial dysfunction and apoptosis in leukemia and lymphoma cells. Cancer Res 2001; 61:5106-15. (Pubitemid 32681542)
18. Dai Y, Landowski TH, Rosen ST, Dent P, Grant S. Combined treatment with the checkpoint abrogator UCN-01 and MEK1/2 inhibitors potently induces apoptosis in drug-sensitive and -resistant myeloma cells through an IL-6-independent mechanism. Blood 2002; 100:3333-43. (Pubitemid 35217085)
19. Dai Y, Rahmani M, Pei XY, Khanna P, Han SI, Mitchell C, et al. Farnesyltransferase inhibitors interact synergistically with the Chk1 inhibitor UCN-01 to induce apoptosis in human leukemia cells through interruption of both Akt and MEK/ERK pathways and activation of SEK1/JNK. Blood 2005; 105:1706-16. (Pubitemid 40223694)
20. Hawkins W, Mitchell C, McKinstry R, Gilfor D, Starkey J, Dai Y, et al. Transient exposure of mammary tumors to PD184352 and UCN-01 causes tumor cell death in vivo and prolonged suppression of tumor regrowth. Cancer Biol Ther 2005; 4:1275-84.
21. Mitchell C, Park MA, Eulitt P, Yang C, Yacoub A, Dent P. PARP1 modulates the lethality CHK1 inhibitors in carcinoma cells. Mol Pharmacol 2010; 78:909-17.
22. Dai Y, Chen S, Shah R, Pei XY, Wang L, Almenara JA, et al. Disruption of Src function potentiates Chk1 inhibitor-induced apoptosis in human multiple myeloma cells in vitro and in vivo. Blood 2010; 117:1947-57.
23. Dai Y, Chen S, Pei XY, Almenara JA, Kramer LB, Venditti CA, et al. Interruption of the Ras/MEK/ERK signaling cascade enhances Chk1 inhibitor-induced DNA damage in vitro and in vivo in human multiple myeloma cells. Blood 2008; 112:2439-49.
24. Dent P, Tang Y, Yacoub A, Dai Y, Fisher PB, Grant S. CHK1 Inhibitors in Combination Chemotherapy: Thinking Beyond the Cell Cycle. Mol Interv 2011; 11:133-40.
25. O'Neill JW, Hockenbery DM. Bcl-2-related proteins as drug targets. Curr Med Chem 2003; 10:1553-62. (Pubitemid 36896556)
26. Golding SE, Rosenberg E, Neill S, Dent P, Povirk LF, Valerie K. Extracellular signal-related kinase positively regulates ataxia telangiectasia mutated, homologous recombination repair and the DNA damage response. Cancer Res 2007; 67:1046-53.
27. Patel V, Lahusen T, Leethanakul C, Igishi T, Kremer M, Quintanilla-Martinez L, et al. Antitumor activity of UCN-01 in carcinomas of the head and neck is associated with altered expression of cyclin D3 and p27(KIP1). Clin Cancer Res 2002; 8:3549-60. (Pubitemid 35340733)
28. Jabbour E, Cortes J, Kantarjian H. Dasatinib for the treatment of Philadelphia chromosome-positive leukaemias. Expert Opin Investig Drugs 2007; 16:679-87. (Pubitemid 46723272)
29. Lee D, Gautschi O. Clinical development of SRC tyrosine kinase inhibitors in lung cancer. Clin Lung Cancer 2006; 7:381-4. (Pubitemid 44043546)
30. Dai Y, Grant S. Targeting multiple arms of the apoptotic regulatory machinery. Cancer Res 2007; 67:2908-11. (Pubitemid 46724822)
31. Cory S, Adams JM. Killing cancer cells by flipping the Bcl-2/Bax switch. Cancer Cell 2005; 8:5-6. (Pubitemid 40991809)
32. Konopleva M, Watt J, Contractor R, Tsao T, Harris D, Estrov Z, et al. Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax). Cancer Res 2008; 68:3413-20.
33. Mitchell C, Yacoub A, Hamed H, Martin AP, Bareford MD, Eulitt P, et al. Inhibition of MCL-1 in breast cancer cells promotes cell death in vitro and in vivo. Cancer Biol Ther 2010; 10:903-17.
34. Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S, et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 2008; 68:3421-8.
35. Nguyen M, Marcellus RC, Roulston A, Watson M, Serfass L, Murthy Madiraju SR, et al. Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc Natl Acad Sci USA 2007; 104:19512-7.
36. Ingley E. Src family kinases: regulation of their activities, levels and identification of new pathways. Biochim Biophys Acta 2008; 1784:56-65.
37. Boutros R, Lobjois V, Ducommun B. CDC25 phosphatases in cancer cells: key players? Good targets? Nat Rev Cancer 2007; 7:495-507. (Pubitemid 46985396)
38. Wang X, Zeng L, Wang J, Chau JF, Lai KP, Jia D, et al. A positive role for c-Abl in Atm and Atr activation in DNA damage response. Cell Death Differ 2010; 18:5-15.
39. Singh J, Aaronson SA, Mlodzik M. Drosophila Abelson kinase mediates cell invasion and proliferation through two distinct MAPK pathways. Oncogene 2010; 29:4033-45.
40. Hamed H, Hawkins W, Mitchell C, Gilfor D, Zhang G, Pei XY, et al. Transient exposure of carcinoma cells to RAS/MEK inhibitors and UCN-01 causes cell death in vitro and in vivo. Mol Cancer Ther 2008; 7:616-29. (Pubitemid 351482144)
41. Carter S, Auer KL, Reardon DB, Birrer M, Fisher PB, Valerie K, et al. Potentiation of Ionizing Radiation induced cell killing by inhibition of the Mitogen Activated Protein (MAP) kinase cascade in A431 human squamous carcinoma cells. Oncogene 1998; 16:2787-96. (Pubitemid 28279345)
42. Mitchell JB, Choudhuri R, Fabre K, Sowers AL, Citrin D, Zabludoff SD. In vitro and in vivo radiation sensitization of human tumor cells by a novel checkpoint kinase inhibitor, AZD7762. Clin Cancer Res 2010; 16:2076-84.
43. Park MA, Yacoub A, Rahmani M, Zhang G, Hart L, Hagan MP, et al. OSU-03012 stimulates PKR-like endoplasmic reticulum-dependent increases in 70-kDa heat shock protein expression, attenuating its lethal actions in transformed cells. Mol Pharmacol 2008; 73:1168-84. (Pubitemid 351439199)
44. Yacoub A, Park MA, Gupta P, Rahmani M, Zhang G, Hamed H, et al. Caspase-, cathepsin- and PERK-dependent regulation of MDA-7/IL-24-induced cell killing in primary human glioma cells. Mol Cancer Ther 2008; 7:297-313. (Pubitemid 351302524)
45. Certo M, Del Gaizo Moore V, Nishino M, Wei G, Korsmeyer S, Armstrong SA, et al. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 2006; 9:351-65. (Pubitemid 43668734)
46. Klinghoffer RA, Sachsenmaier C, Cooper JA, Soriano P. Src family kinases are required for integrin but not PDGFR signal transduction. EMBO J 1999; 18:2459-71. (Pubitemid 29213279)